HEARING aid maker Cochlear has revealed that almost 2 per cent of its Nucleus C1500 units - a range of implants recalled by the company - have failed.
The group's shares surged yesterday after it declared that it had identified the cause of the problem with one line in the range that prompted a recall in September. Cochlear said the failure rate was similar in all three regions of the Americas, Europe, Middle East and Africa, and Asia Pacific. Management said 1.9 per cent of registered hearing aids in the range had failed. The C1500 devices were recalled voluntarily by Cochlear in September after an increase in failures of its Nucleus C1512 implants, which was part of the series. Cochlear said that specific microelectronic components, typically one of four diodes, had malfunctioned because "microcracks" had allowed water molecules to enter the implant. The microcracks were caused during manufacturing by "unexpected variations" in the process known as brazing - where a conductor is joined to a titanium chassis in the implant. Cochlear reiterated that its Nucleus C124RE and Nucleus C1422 implants were not affected. The group's shares soared 16 per cent yesterday to $64.33. It is the highest closing price for Cochlear shares since it issued the recall halfway through September.
|